Janne Lehtiö

Karolinska Institutet

Scientific Lead for Precision Medicine and DDLS Precision Medicine Area Lead

Key publications

Stratmann S, Vesterlund M, Umer HM, Eshtad S, Skaftason A, Herlin MK, Sundström C, Eriksson A, Höglund M, Palle J, Abrahamsson J, Jahnukainen K, Munthe-Kaas MC, Zeller B, Tamm KP, Lindskog C, Cavelier L, Lehtiö J, Holmfeldt L. Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children. Leukemia 2023 Mar;37(3):550-559. https://doi.org/10.1038/s41375-022-01796-7

Babačić H, Christ W, Araújo JE, Mermelekas G, Sharma N, Tynell J, García M, Varnaite R, Asgeirsson H, Glans H, Lehtiö J, Gredmark-Russ S, Klingström J, Pernemalm M., Comprehensive proteomics and meta-analysis of COVID-19 host respons. Nature Comm 2023, 14, 5921. https://doi.org/10.1038/s41467-023-41159-z

Herbst SA*, Vesterlund M*, Helmboldt AJ, Jafari R, Siavelis I, Stahl M, Schitter EC, Liebers N, Brinkmann BJ, Czernilofsky F, Roider T, Bruch PM, Iskar M, Kittai A, Huang Y, Lu J, Richter S, Mermelekas G, Umer HM, Knoll M, Kolb C, Lenze A, Cao, Österholm C, Wahnschaffe L, Herling C, Scheinost S, Ganzinger M, Mansouri L, Kriegsmann K, Kriegsmann M, Anders S, Zapatka M, Del Poeta G, Zucchetto A, Bomben R, Gattei V, Dreger P, Woyach J, Herling M, Müller-Tidow C, Rosenquist R, Stilgenbauer S, Zenz T, Huber W, Tausch E, Lehtiö J§ and Dietrich D§. Proteogenomics refines the molecular classification of chronic lymphocytic leukemia. Nature Comm. 2022 Oct 20;13(1):6226 (§ shared last author). https://doi.org/10.1038/s41467-022-33385-8

Tamborero D, Dienstmann R, Rachid M.J, Boekel J, Lopez-Fernandez A, Jonsson M,  Razzak A, Braña I, De Petris L, Yachnin J, Baird RD, Loriot Y, Massard C, Martin-Romano P, Opdam F, Schlenk RF, Vernieri C, Masucci M, Villalobos X, Chavarria E, Cancer Core Europe consortium, Balmaña J, Apolone G, Caldas C, Bergh J, Ernberg I, Fröhling S, Garralda E, Karlsson C, Tabernero J, Voest E, Rodon J, Lehtiö J. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nature Cancer 2022, Feb;3(2):251-261. https://doi.org/10.1038/s43018-022-00332-x

Lehtiö J*, Arslan T, Siavelis I, Pan Y, Socciarelli F, Berkovska O, Umer HM, Mermelekas G,  Pirmoradian M, Jönsson M, Brunnström H, Brustugun OT, Pinganksha Purohit K , Cunningham R, Foroughi H, Isaksson S, Arbajian E, Aine M, Karlsson A, Kotevska M, Hansen CG, Drageset Haakensen V, Helland Å, Tamborero D, Johansson HJ, Branca RMM, Planck M, Staaf J,  Orre LM. Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms. Nature Cancer, 2021Nov;2(11):1224-1242. (*corresponding author) https://doi.org/10.1038/s43018-021-00259-9

Tamborero D, Dienstmann R, Rachid MH, Boekel J, Baird R, Braña I, De Petris L, Yachnin J, Massard C, Opdam FL, Schlenk R, Vernieri C, Garralda E, Masucci M, Villalobos X, Chavarria E; Cancer Core Europe consortium, Calvo F, Fröhling S, Eggermont A, Apolone G, Voest EE, Caldas C, Tabernero J, Ernberg I, Rodon J, Lehtiö J. Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. Nature Medicine. 2020 Jul;26(7):992-994. https://doi.org/10.1038/s41591-020-0969-2

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans CD, Brismar H, Haukaas TH, Bathen TF, Schlichting E, Naume B, OSBREAC, Luders T, Borgen E, Kristensen VN, Russnes HG, Lingjærde OC, Mills GB, Sahlberg KK, Børresen-Dale A.L, Lehtiö J., Breast cancer quantitative proteome and proteogenomic landscape. Nature Comm, 10 Apr, 2019. https://doi.org/10.1038/s41467-019-09018-y

Orre LM, Vesterlund M, Pan Y, Arslan T,  Zhu Y, Fernandez Woodbridge A, Frings O, Fredlund E, Lehtiö J. SubCellBarCode: Proteome-wide mapping of protein localization and relocalization. Molecular Cell. 2019 Jan 3. https://doi.org/10.1016/j.molcel.2018.11.035

Zhu Y, Orre LM, Johansson HJ, Huss M, Boekel J, Vesterlund M, Fernandez-Woodbridge A, Branca RMM, Lehtiö J. Discovery of coding regions in the human genome by integrated proteogenomics analysis workflow. Nature Commun. 2018 Mar 2;9(1):903. https://doi.org/10.1038/s41467-018-03311-y

Janne Lehtiö

Professor, Karolinska Institutet
Scientific Lead for Precision Medicine and DDLS Precision Medicine Area Lead, SciLifeLab
Platform Scientific Director, Proteomics, SciLifeLab

Research interests

Proteomics is a collective name of several techniques and methods for global/systemic analysis of proteins. Mass spectrometry (MS) based proteomics is an important research field that drives proteome systems biology and generates phenotypic information at the molecular level.

Our Cancer Proteomics Mass Spectrometry group, headed by Professor Janne Lehtiö, is continuously developing mass spectrometry and bioinformatics methods for proteome and systems biology analysis to understand and improve cancer therapy. We develop methods to increased proteome coverage on clinical samples, including increased peptide coverage/protein to study protein variants. This can be illustrated by our developed high resolution isoelectric focusing (HiRIEF) method, which improves the analytical depth in proteomics substantially and allows for search space reduction to enable human proteogenomics. Proteogenomics is an emerging exciting field in MS-based proteomics that combines sample specific information from genomic sequencing, transcriptomics and MS-based proteomics. We use proteogenomics to gain knowledge on how genome changes in cancer influence the proteome level. We have pioneered in developing proteogenomics methods and applied them for cancer proteomics by demonstrating that the method can be used to discover new protein coding loci, such as new gene variants, expressed pseudogenes and long non-coding RNA proteins. This opens up completely new opportunities to develop and improve cancer therapy e.g. immunotherapy.

Our main application focus using proteomics is within the field of breast cancer, lung cancer and leukemia. In summary, we aim to use the proteome information to develop predictive analytical tools and new molecular biomarkers to enable selection of the most effective therapy for each cancer patient.

Group members

Group leader

Janne Lehtiö, Professor, PI, Karolinska Institutet
Scientific Director, Science for Life Laboratory

Principal Researchers

Jenny Forshed, PhD
Rozbeh Jafari, PhD
Henrik Johansson, PhD
Lukas Orre, PhD
David Tamborero, PhD

Senior Researcher

Rui Branca, PhD
Senior Research Specialist
Yanbo Pan, PhD

Postdoctoral researchers

Haris Babacic, MD, PhD
Akram Emdadi PhD
Soumitra Marathe, PhD
Xuekang Qi, PhD
Ioannis Siavelis, MD, PhD
Amare Wolide, PhD

PhD students

Olena Berkovska
George Field
Yaroslav Kaminskiy
Isabelle Leo
Igor Schliemann
Justin Seby
Noora Sissala
Irene Villanueva Sanz

Master students

Kovi Govindarajan

Research Infrastructure Specialists

Eduardo Araújo, PhD
Xiaofang Cao, PhD
Georgios Mermelekas, PhD
Mahshid Zarrineh, PhD

Research engineers

Mahnaz Nikpour, PhD
Rita Hutyra-gram

Bioinformatician

Luay Assad, PhD

Software developers

Jorrit Boekel, PhD
Laura Gheorghe
Markus Jonsson
Ali Razzak
Dmitrii Rudakovskii

Affiliated to research

Armando Bartolazzi, PhD
Santeri Kiviluoto, PhD

Hospital laboratory coordinator

Ghazaleh Assadi, PhD

Senior Laboratory manager

Laura Levi, PhD

Research coordinators

Helena Bäckvall, PhD
Xenia Villalobos Alberú, PhD

Administrator

Simon Rapple

Contact

janne.lehtio@scilifelab.se

simon.rapple@ki.se

Last updated: 2024-10-18

Content Responsible: admin(website@scilifelab.se)